AI Article Synopsis

  • The study investigates the effectiveness of combining two vasodilator drugs, macitentan and vardenafil, for treating pulmonary arterial hypertension (PAH), as monotherapy often has limited impact.
  • Human pulmonary arteries and veins were tested in an organ bath to evaluate how these drugs affected blood vessel contractions induced by endothelin-1 and norepinephrine.
  • Results showed that when used together, macitentan and vardenafil significantly reduced blood vessel contraction more effectively than either drug alone, while the metabolite ACT-132577's effects were not enhanced by vardenafil.

Article Abstract

Purpose: Treatment of pulmonary arterial hypertension (PAH) by vasodilator drug monotherapy is often limited in its effectiveness. Combination therapy may help to improve treatment and to reduce drug toxicity. This study assessed the combination of the endothelin receptor antagonist macitentan and the phosphodiesterase-5 inhibitor vardenafil in a human ex vivo model.

Methods: Study patients did not suffer from PAH. Human pulmonary arteries (PA) and veins (PV) were harvested from resected pulmonary lobes. Contractile forces of blood vessel segments in the presence and absence of the vasodilator drugs macitentan, its main metabolite ACT-132577, and vardenafil were determined isometrically in an organ bath.

Results: Macitentan 1E-7 M was sufficient to significantly abate endothelin-1-induced vasoconstriction in PA. A concentration of 1E-6 M was required for significant effects of macitentan on PV and of ACT-132577 on both vessel types. Combination of 1E-7 M macitentan and 1E-6 M vardenafil inhibited sequential constriction with endothelin-1 and norepinephrine of PA significantly more than either compound alone. Effects of 3E-7 M and 1E-6 M macitentan and effects of all doses of ACT-132577 were not further enhanced by 1E-6 M vardenafil.

Conclusions: These data suggest that vasodilator effects of macitentan and vardenafil combined may surpass monotherapy in vivo if drug doses are adjusted properly. Vasodilation by the longer-acting metabolite ACT-132577 was not further enhanced by vardenafil.

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10557-019-06868-yDOI Listing

Publication Analysis

Top Keywords

combination therapy
8
pulmonary arterial
8
arterial hypertension
8
macitentan
8
human vivo
8
metabolite act-132577
8
effects macitentan
8
act-132577 enhanced
8
vardenafil
6
combination
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!